Page 222 - Read Online

Page 6 of 7 Leon et al. Neuroimmunol Neuroinflammation 2018;5:30 I http://dx.doi.org/10.20517/2347-8659.2018.26

I, Tsolaki M, Mecocci P, Spenger C, Villemagne VL, Masters CL, Muehlboeck Js, Bäckman L, Fratiglioni L, Kalpouzos G, Wahlund L,
Schumann G, Lovestone S, Williams SC, Westman E, Simmons A; Alzheimer’s Disease Neuroimaging Initiative; AddNeuroMed Con-
sortium, Australian, Imaging, Biomarkers, and Lifestyle Study Research Group; IMAGEN consortium. A multicohort study of ApoE e4
and amyloid-B effects on the hippocampus in Alzheimer’s disease. J Alzheimers Dis 2017;56:1159-74.
11. Bu G. Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009;10:333-
44.
12. Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med 2016;94:739-46.
13. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
14. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofi-
brillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991;541:163-6.
15. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate
AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid-b peptide clearance.
Sci Transl Med 2011;3:89ra57.
16. Chetty PS, Mayne L, Lund-Katza S, Englander SW, Phillips MC. Helical structure, stability, and dynamics in human apolipoprotein E3
and E4 by hydrogen exchange and mass spectrometry. Proc Natl Acad Sci U S A 2017;114:968-73.
17. Dong LM, Weisgraber KH. Human apolipoprotein E4 domain interaction: arginine 61 and glutamic acid 255 interact to direct the pref-
erence for very low density lipoproteins. J Biol Chem 1996;271:19053-7.
18. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
19. Urfer-Buchwalder A, Urfer R. Identification of a NRF1 recognition motif in the ApoE4 variant linked to AD. Sci Rep 2017;7:40668.
20. Chu Q, Diedrich JK, Vaughan JM, Donaldson CJ, Nunn MF, Lee KF, Saghatelian A. HtrA1 proteolysis of ApoE in vitro is allele selec-
tive. J Am Chem Soc 2016;138:9473-8.
21. Lane-Donovan C, Herz J. ApoE, ApoE receptors, and the synapse in Alzheimer’s disease. Trends Endocrinol Metab 2016;28:273-84.
22. Pohlkamp T, Wasser CR, Herz J. Functional roles of the interaction of APP and lipoprotein receptors. Front Mol Neurosci 2017;10:54.
23. Fan QW, Iosbe I, Asou H, Yanagisawa K, Michikawa M. Expression and regulation of apolipoprotein E receptors in the cells of the cen-
tral nervous system in culture: a review. J Am Aging Assoc 2001;24:1-10.
24. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. Overexpression of low-
density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron
2009;64:632-44.
25. Fryer JD, Demattos RB, McCormick LM, O’Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman
DM. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not
modify amyloid plaque pathology in PDAPP mice. J Biol Chem 2005;280:25754-9.
26. Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Low-density lipoprotein receptor represents an apolipoprotein E-independent
pathway of Ab uptake and degradation by astrocytes. J Biol Chem 2012;287:13959-71.
27. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM. Apolipoprotein E pro-
motes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004;10:719-26.
28. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006;8:445-54.
29. Huang YA, Zhou B, Wernig M, Südhof TC. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Ab secretion. Cell
2017;168:427-41.e21.
30. Maurice R, Marcel YL, Innerarity TL, Milne RW. A potential complication in the use of monoclonal antibodies: inhibition of apoB-
mediated receptor binding by an anti-apoE antibody. J Lipid Res 1989;30:587-96.
31. Raffai R, Weisgraber KH, MacKenzie R, Rupp B, Rassart E, Hirama T, Innerarity TL, Milne R. Binding of an antibody mimetic of the
human low density lipoprotein receptor to apolipoprotein E is governed through electrostatic forces. J Biol Chem 2000;275:7109-16.
32. Grothe MJ, Villeneuve S, Dyrba M, Bartres-Faz D, Wirth M. Multimodal characterization of older APOE2 carriers reveals selective re-
duction of amyloid load. Neurology 2017;88:569-76.
33. Xue-Shan Z, Juan P, Qi W, Zhong R, Li-Hong P, Zhi-Han T, Zhi-Sheng J, Gui-Xue W, Lu-Shan L. Imbalanced cholesterol metabolism
in Alzheimer’s disease. Clin Chim Acta 2016;456:107-14.
34. Suri S, Heise V, Trachtenberg AJ, Mackay CE. The forgotten APOE allele: a review of the evidence and suggested mechanisms for the
protective effect of APOE e2. Neurosci Biobehav Rev 2013;37:2878-86.
35. Hamanaka H, Katoh-Fukui Y, Suzuki K, Kobayashi M, Suzuki R, Motegi Y, Nakahara Y, Takeshita A, Kawai M, Ishiguro K, Yokoyama
M, Fujita SC. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Hum Mol Genet 2000;9:353-61.
36. Wilson RS, Bienias JL, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E epsilon 2 allele and decline in episodic memory.
J Neurol Neurosurg Psychiatry 2002;73:672-7.
37. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabo-
lism before and after plaque formation in a mouse model of Alzheimer’s disease. Neurobiol Dis 2002;9:305-18.
38. Drouet B, Fifre A, Pinçon-Raymond M, Vandekerckhove J, Rosseneu M, Guéant JL, Chambaz J, Pillot T. ApoE protects cortical neu-
rones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloidbeta peptide. J Neurochem 2001;76:117-27.
39. Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, Weeber EJ, Turner RS, Xu B, Rebeck GW, Hoe HS. ApoE4
decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci 2009;29:15317-22.
40. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-
amyloid peptides. Nat Genet 1996;14:55-61.
41. Zhong N, Weisgraber KH. Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. J Biol
Chem 2009;284:6027-31.
42. Xu Q, Brecht WJ, Weisgraber KH, Mahley RW, Huang Y. Apolipoprotein E4 domain interaction occurs in living neuronal cells as deter-